FDA seeks warning labels for two diabetes drugs

Share this content:

The Food and Drug Administration wants two diabetes drugs to have strict warning labels because of their risk for congestive heart failure in certain patients.

The FDA is seeking a "black box" warning for the drugs Avandia and Actos because the products are being prescribed to patients who already have significant heart problems. FDA Commissioner Andrew von Eschenbach argued for the warning labels in congressional testimony this week.

A recently published New England Journal of Medicine study suggested that Avandia may increase the risk of heart attack and heart-related deaths. Actos is in the same drug class as Avandia.